<DOC>
	<DOC>NCT02393924</DOC>
	<brief_summary>This study is to observe the different anti-cancer treatment regimens and their sequencing throughout the course of the disease in patients with unresectable locally advanced (LA) or metastatic breast cancer (mBC) and to describe the clinical outcome for each treatment regimen measured as progression-free survival (PFS).</brief_summary>
	<brief_title>ESTHER: Her2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Initially diagnosed with HER2positive unresectable LA/mBC no more than 6 months prior to enrolment, although they can have received anticancer treatment during that time Age 18 years and older There are no exclusion criteria for entry into this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>